C-144-01

Metastatic Melanoma

Prospective, 3-cohort interventional study evaluating autologous tumor infiltrating lymphocyte (TIL) infusion (LN-144-01) followed by IL-2 after a non-myeloablative chemotherapy preparative regimen for the treatment of patients with metastatic melanoma.

NOW RECRUITING: Iovance is conducting a Phase 2 clinical trial to assess the safety, efficacy and feasibility of an adoptive cell therapy based on autologous TIL (LN-144-01), followed by IL-2, in the treatment of patients with refractory metastatic melanoma. The multi-center, single-arm trial is now recruiting patients at various sites in the US.

Key eligibility criteria:
• Measurable metastatic melanoma and ≥ 1 lesion resectable for TIL generation
• At least one prior systemic therapy
• Age ≥ 18
• ECOG PS 0-1

Endpoints:
• Primary: Safety
• Secondary: Efficacy defined as ORR, CRR, PFS, DOR and OS

Physicians

To learn more about the trial on ClinicalTrials.gov, including eligibility criteria, locations and contacts, please click here:

Identifier: NCT02360579

Clinical.Inquiries@iovance.com
1-866-565-4410

Patients

If you have been diagnosed with metastatic melanoma, have previously undergone at least one systemic treatment, and are interested in participating in this trial, please talk to your doctor.

If you have other questions or would like more information on this trial:

ClinicalTrials.gov